These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 21900936)

  • 1. Resolving controversies on the path to Alzheimer's therapeutics.
    Selkoe DJ
    Nat Med; 2011 Sep; 17(9):1060-5. PubMed ID: 21900936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease.
    Haas C
    J Alzheimers Dis; 2012; 28(2):241-81. PubMed ID: 21987594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.
    Karran E; Mercken M; De Strooper B
    Nat Rev Drug Discov; 2011 Aug; 10(9):698-712. PubMed ID: 21852788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
    Saxena U
    Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity.
    Mullane K; Williams M
    Curr Protoc Pharmacol; 2019 Mar; 84(1):e57. PubMed ID: 30802363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will anti-amyloid therapies work for Alzheimer's disease?
    St George-Hyslop PH; Morris JC
    Lancet; 2008 Jul; 372(9634):180-2. PubMed ID: 18640437
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
    Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
    Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.
    Liu J; Yang B; Ke J; Li W; Suen WC
    Drugs Aging; 2016 Oct; 33(10):685-697. PubMed ID: 27699633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
    Adlard PA; James SA; Bush AI; Masters CL
    Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.
    Selkoe DJ
    Ann N Y Acad Sci; 2000; 924():17-25. PubMed ID: 11193794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
    Town T
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroscience. An antibiotic to treat Alzheimer's?
    Helmuth L
    Science; 2000 Nov; 290(5495):1273-4. PubMed ID: 11185394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
    Tarawneh R; Holtzman DM
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metal chelator decreases Alzheimer beta-amyloid plaques.
    Gouras GK; Beal MF
    Neuron; 2001 Jun; 30(3):641-2. PubMed ID: 11430794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid beta-peptide is produced by cultured cells during normal metabolism: a reprise.
    Selkoe DJ
    J Alzheimers Dis; 2006; 9(3 Suppl):163-8. PubMed ID: 16914855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
    Hampel H; Shen Y; Walsh DM; Aisen P; Shaw LM; Zetterberg H; Trojanowski JQ; Blennow K
    Exp Neurol; 2010 Jun; 223(2):334-46. PubMed ID: 19815015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease.
    Wilcock DM
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):386-94. PubMed ID: 20522016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
    Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
    Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sting of Alzheimer's failures offset by upcoming prevention trials.
    Mullard A
    Nat Rev Drug Discov; 2012 Sep; 11(9):657-60. PubMed ID: 22935790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.